
1. nat med. 2020 oct;26(10):1602-1608. doi: 10.1038/s41591-020-1005-2. epub 2020 aug
3.

emergence clonal expansion vitro artemisinin-resistant plasmodium
falciparum kelch13 r561h mutant parasites rwanda.

uwimana a(1), legrand e(2), stokes bh(3), ndikumana jm(4), warsame m(5), umulisa 
n(6)(7), ngamije d(8), munyaneza t(9), mazarati jb(9), munguti k(10), campagne
p(11), criscuolo a(11), ariey f(12), murindahabi m(13), ringwald p(14), fidock
da(3)(15), mbituyumuremyi a(4), menard d(16).

author information: 
(1)malaria parasitic diseases division, rwanda biomedical centre (rbc),
kigali, rwanda. aline.uwimana@rbc.gov.rw.
(2)malaria genetics resistance unit, institut pasteur, paris, france.
(3)department microbiology immunology, columbia university irving medical 
center, new york, usa.
(4)malaria parasitic diseases division, rwanda biomedical centre (rbc),
kigali, rwanda.
(5)university gothenburg, gothenburg, sweden.
(6)maternal child survival program/jhpiego, baltimore, md, usa.
(7)impact malaria rwanda, kigali, rwanda.
(8)ministry health, kigali, rwanda.
(9)national reference laboratory (nrl), bios /rwanda biomedical centre (rbc),
kigali, rwanda.
(10)us president's malaria initiative, kigali, rwanda.
(11)hub de bioinformatique et biostatistique-département biologie
computationnelle, paris, france.
(12)inserm 1016, institut cochin, service de parasitologie-mycologie, hôpital
cochin, université de paris, paris, france.
(13)roll back malaria west central africa, kigali, rwanda.
(14)global malaria programme, world health organization, geneva, switzerland.
(15)division infectious diseases, department medicine, columbia university 
irving medical center, new york, ny, usa.
(16)malaria genetics resistance unit, institut pasteur, paris, france.
dmenard@pasteur.fr.

artemisinin resistance (delayed p. falciparum clearance following
artemisinin-based combination therapy), widespread across southeast asia but
to date reported africa1-4. genotyped p. falciparum
k13 (pfkelch13) propeller domain, mutations mediate artemisinin
resistance5,6, pretreatment samples collected recent
dihydroarteminisin-piperaquine artemether-lumefantrine efficacy trials in
rwanda7. cure rates >95% treatment arms, pfkelch13 r561h
mutation identified 19 257 (7.4%) patients masaka. phylogenetic
analysis revealed expansion indigenous r561h lineage. gene editing
confirmed mutation drive artemisinin resistance vitro. this
study provides evidence de novo emergence pfkelch13-mediated
artemisinin resistance rwanda, potentially compromising continued success 
of antimalarial chemotherapy africa.

doi: 10.1038/s41591-020-1005-2 
pmcid: pmc7541349
pmid: 32747827 

